German Distributor Appointed

Deltex Medical Group PLC
08 December 2004



                            Deltex Medical Group plc



                Appointment of German distributor for CardioQ(TM)





8 December 2004:  Deltex Medical Group plc ('Deltex Medical'), the haemodynamic
monitoring company, announces the appointment of P. J. Dahlhausen & Co. GmbH
(Dahlhausen) as its distributor partner for CardioQ in Germany with immediate
effect.



Dahlhausen, based in Cologne, has manufactured and distributed medical devices
throughout Germany for 150 years and has a strong reputation with hospitals
across the country.  They have a substantial field sales and clinical support
force of 25 people covering all German hospitals.



Germany's healthcare system is emerging from a period of significant
reorganisation following the implementation of new funding and reimbursement
systems aimed at addressing systemic cost and efficiency issues. Prior to
entering into this arrangement, Dahlhausen's senior management asked their sales
and marketing team to undertake a detailed evaluation of the potential for
haemodynamic optimisation in Germany. This evaluation concluded that the proven
economic and clinical benefits derived from the use of Deltex Medical's CardioQ
monitor fit well with the new German healthcare regime. Dahlhausen also believes
that the novel sales approaches developed by Deltex Medical for the UK market
can effectively be tailored to fit the specific characteristics of the German
market place.



Chief Executive, Andy Hill commented:



'Germany is the final European territory in our strategic sales and distribution
roll-out of CardioQ.  While Germany represents the biggest medical technology
market in Europe, it is also one of the more complex environments to do business
in. Dahlhausen have demonstrated that they clearly understand the difficulties
of their market and have the resources, human and intellectual, to create a
successful platform from which to launch our products. I believe that our
collaboration with Dahlhausen will help German doctors and healthcare managers
to deliver to patients undergoing moderate and major surgery the highest quality
care in the most cost effective manner.'



Peter Dahlhausen, Managing Director of P. J. Dahlhausen & Co. GmbH commented:



'I am delighted that Dahlhausen will be working with Deltex Medical and look
forward to developing a successful long-term relationship with the company.
Feedback about the CardioQ from the sales and marketing team and our customers
has been consistently positive and I believe we have a real opportunity to
establish haemodynamic optimisation, using the CardioQ, as a standard of care
for moderate and major surgery in Germany.  Our initial focus will be on
establishing wide-scale use of the CardioQ in selected key hospitals.'




For further information, please contact:-

Deltex Medical Group plc                       01243 774 837
Nigel Keen, Chairman                           [e-mail]
Andy Hill, Chief Executive                     [e-mail]
Ewan Phillips, Finance Director                [e-mail]

Financial Dynamics                             0207 831 3113
David Yates                                    [e-mail]
Lucy Briggs                                    [e-mail]



Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.



There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-



•         validated the results of the Monitor against known standards for
measuring cardiac output, demonstrating that the technology works



•         proved that the CardioQ works in a wide range of surgical procedures



•         demonstrated that the Company's technology provides significant health
and economic benefits by helping to reduce post-operative complications and
length of hospital stays by an average of 30 to 40 per cent for a wide range of
patients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange